Azathioprine in the treatment of systemic lupus erythematosus. A three-year prospective study |
| |
| Authors: | A. J. G. Swaak L. W. Statius Van Eps L. A. Aarden T. E. W. Feltkamp |
| |
| Affiliation: | (1) Department of Internal Medicine, Slotervaart Hospital, Amsterdam;(2) Department of Autoimmune Disease of the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology of the University of Amsterdam, Amsterdam;(3) Department of Rheumatology, Dr. Daniel den Hoed Kliniek, Rotterdam, The Netherlands |
| |
| Abstract: | Summary In a prospective study, the effect of azathioprine on the clinical course and the anti-dsDNA profile was evaluated in 17 patients with systemic lupus erythematosus (SLE). During this prospective longitudinal study, exacerbations were never observed. Three periods of continuous anti-dsDNA increases with a doubling time (T2) shorter than 10 weeks were noted. Both the clinical symptoms and the anti-dsDNA levels improved after the administration of azathioprine. These results necessitate a careful double-blind trial for the use of this drug to prevent SLE exacerbations. |
| |
| Keywords: | Azathioprine Systemic Lupus Erythematosus Anti-dsDNA |
| 本文献已被 SpringerLink 等数据库收录！ |
